Showing 3571-3580 of 5910 results for "".
- Johnson & Johnson Vision Care Introduces Acuvue RevitaLens Multi-Purpose Disinfecting Solutionhttps://modernod.com/news/johnson-johnson-vision-care-introduces-acuvue-revitalens-multi-purpose-disinfecting-solution/2476925/Johnson & Johnson Vision has unveiled the first extension of the Acuvue brand name beyond contact lenses with the launch of Acuvue RevitaLens Multi-Purpose Disinfecting Solution (MPDS). Acuvue RevitaLens MPDS delivers disinfection and all-day comfort for reusable contact lens wearers. Its dua
- US House Speaker Nancy Pelosi Introduces Plan to Permit Price Negotiation for Some Drugshttps://modernod.com/news/us-house-speaker-nancy-pelosi-introduces-plan-to-permit-price-negotiation-for-some-drugs/2476901/US House Speaker Nancy Pelosi on Thursday unveiled proposed legislation that would permit the federal government to negotiate prices of drugs for Medicare and other health programs. Specifically, the proposal would empower the Department of Health and Human Services (HHS) to annually ne
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- Oculus Release Myopia Master for Myopia Managementhttps://modernod.com/news/oculus-release-myopia-master-for-myopia-management/2476839/Oculus has introduced the Myopia Master, a device designed to combine all the important measurement methods of myopia management: axial length, refraction values, and the central corneal radii. The Oculus Myopia Master creates a myopia report for each patient, giving due consideration to s
- OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113 in a Mouse Model of Dry Eye Diseasehttps://modernod.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/OKYO Pharma has announced potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of dry eye disease (DED) in mice. These preclinical efficacy data, identifying a lead drug candidate, will facilitate initiation of clinical
- Staar Surgical Announces FDA IDE Clinical Study Approvalhttps://modernod.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/Staar Surgical announced that the FDA, in a letter dated August 23, 2019, stated that it has determined that Staar has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ Visian Implantable Collamer Lens for myopia, and EVO/EVO+ Visian Tor
- Oculus Introduces Pentacam AXL Wavehttps://modernod.com/news/oculus-introduces-pentacam-axl-wave/2479548/Oculus has announced that it plans to introduce its next-generation Pentacam—the Pentacam AXL Wave. The new Pentacam AXL Wave is the first device to combine Scheimpflug tomography with axial length, total eye wavefront, objective refraction, and retroillumination, according to Oculus. New
- Glaukos Announces Agreement to Buy Avedro in All-Stock Dealhttps://modernod.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/In a move to diversify its offerings and expand its corneal health franchise, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction.